# A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

> **NCT06888921** · PHASE1,PHASE2 · RECRUITING · sponsor: **Compugen Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Ovarian Cancer
- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** COM701
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT06888921
- **Lead sponsor:** Compugen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-21
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888921, "A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT06888921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*